Voyager Acquisition Corporation Reports 99.67% Share Redemptions Ahead of VERAXA Biotech Merger

Voyager Acquisition Corporation (NASDAQ: "VACHU," "VACH," "VACHW") reported that holders of 25,217,315 Class A ordinary shares exercised their redemption rights in connection with the company's planned business combination with VERAXA Biotech AG. This represents approximately 99.67% of the shares outstanding, indicating overwhelming shareholder preference for redemption rather than participation in the merger. Following these redemptions, only approximately $885,556 will remain in Voyager's trust account, a significant reduction from the typical SPAC trust amounts that often exceed $100 million. The remaining 82,685 Class A shares will convert into shares of VERAXA Biotech Holding AG upon completion of the transaction.

The combined company is expected to trade on Nasdaq under the ticker symbol "VRXA" once the merger is finalized. This development represents a substantial shift in the financial structure of what was intended to be a special purpose acquisition company merger. Voyager Acquisition Corporation described itself as having a mission to revolutionize the healthcare sector through mergers or business combinations, with experienced executives in investing, operations, and medical innovation. The company maintained a website at https://www.voyageracq.com where additional information was available.

The announcement was distributed through BioMedWire, a specialized communications platform focusing on biotechnology, biomedical sciences, and life sciences developments. BioMedWire operates as one of more than 75 brands within the Dynamic Brand Portfolio at IBN, providing various distribution services including access to wire solutions through InvestorWire, article syndication to over 5,000 outlets, enhanced press release services, social media distribution, and corporate communications solutions. The platform's website at https://www.BioMedWire.com contains additional information about their services and full terms of use and disclaimers applicable to all content they distribute at https://www.BioMedWire.com/Disclaimer.

The high redemption rate raises questions about investor confidence in the VERAXA Biotech merger specifically and potentially about market conditions for SPAC transactions more broadly. With only minimal funds remaining in the trust account, VERAXA Biotech will receive substantially less capital than typically expected in such transactions, which could impact the combined company's ability to execute its business plans and growth strategies. The transaction's completion will now depend on alternative financing arrangements or the company's ability to operate with significantly reduced capital resources compared to initial expectations when the SPAC was formed.